JP2021510702A5 - - Google Patents

Info

Publication number
JP2021510702A5
JP2021510702A5 JP2020538844A JP2020538844A JP2021510702A5 JP 2021510702 A5 JP2021510702 A5 JP 2021510702A5 JP 2020538844 A JP2020538844 A JP 2020538844A JP 2020538844 A JP2020538844 A JP 2020538844A JP 2021510702 A5 JP2021510702 A5 JP 2021510702A5
Authority
JP
Japan
Prior art keywords
inhibitor
product according
conjugate
pharmaceutical product
effective amount
Prior art date
Application number
JP2020538844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510702A (ja
JPWO2019140271A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/013314 external-priority patent/WO2019140271A2/en
Publication of JP2021510702A publication Critical patent/JP2021510702A/ja
Publication of JPWO2019140271A5 publication Critical patent/JPWO2019140271A5/ja
Publication of JP2021510702A5 publication Critical patent/JP2021510702A5/ja
Priority to JP2023186470A priority Critical patent/JP7703001B2/ja
Pending legal-status Critical Current

Links

JP2020538844A 2018-01-12 2019-01-11 相乗的がん治療 Pending JP2021510702A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023186470A JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862617095P 2018-01-12 2018-01-12
US62/617,095 2018-01-12
US201862674483P 2018-05-21 2018-05-21
US62/674,483 2018-05-21
US201862700147P 2018-07-18 2018-07-18
US62/700,147 2018-07-18
US201862711423P 2018-07-27 2018-07-27
US201862711421P 2018-07-27 2018-07-27
US62/711,423 2018-07-27
US62/711,421 2018-07-27
US201862716788P 2018-08-09 2018-08-09
US201862716796P 2018-08-09 2018-08-09
US62/716,796 2018-08-09
US62/716,788 2018-08-09
PCT/US2019/013314 WO2019140271A2 (en) 2018-01-12 2019-01-11 Synergistic cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023186470A Division JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Publications (3)

Publication Number Publication Date
JP2021510702A JP2021510702A (ja) 2021-04-30
JPWO2019140271A5 JPWO2019140271A5 (https=) 2022-01-19
JP2021510702A5 true JP2021510702A5 (https=) 2022-01-19

Family

ID=67218383

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020538819A Pending JP2021510701A (ja) 2018-01-12 2019-01-11 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤
JP2020538844A Pending JP2021510702A (ja) 2018-01-12 2019-01-11 相乗的がん治療
JP2023186470A Active JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020538819A Pending JP2021510701A (ja) 2018-01-12 2019-01-11 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023186470A Active JP7703001B2 (ja) 2018-01-12 2023-10-31 相乗的がん治療

Country Status (10)

Country Link
US (4) US20200360545A1 (https=)
EP (2) EP3737383A4 (https=)
JP (3) JP2021510701A (https=)
KR (2) KR20200109345A (https=)
CN (2) CN111587126A (https=)
AU (2) AU2019208024A1 (https=)
CA (2) CA3087628A1 (https=)
MX (3) MX2020007306A (https=)
RU (1) RU2020126774A (https=)
WO (2) WO2019140266A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
CN114615978A (zh) * 2019-08-28 2022-06-10 普罗林科斯有限责任公司 Dna损伤响应的偶联抑制剂
CN119213060A (zh) * 2022-04-14 2024-12-27 国立研究开发法人量子科学技术研究开发机构 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒
WO2024030998A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Methods of treating cancer with long-acting topoisomerase i inhibitor
WO2024031005A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Treating cancer with long-acting topoisomerase i inhibitor

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030575A1 (en) 1997-01-08 1998-07-16 Proligo Llc Bioconjugation of macromolecules
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20040176270A1 (en) 2002-07-12 2004-09-09 Biomarin Pharmaceutical Inc. Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
EP1580216B1 (en) 2002-10-31 2014-05-14 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
ES2629696T3 (es) 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
MX2009002855A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
WO2009141826A2 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
CA2738807A1 (en) 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
JP2012509469A (ja) 2008-11-18 2012-04-19 バクスター・インターナショナル・インコーポレイテッド ポリエチレングリコールサンプルの多分散度および／または分子量分布を決定する方法
WO2010138719A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
ME03396B (me) 2009-11-18 2020-01-20 Nektar Therapeutics Oblici kisele soli konjugata polimer-lek
EP2566335B1 (en) 2010-05-05 2016-06-29 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
TW201215412A (en) 2010-08-30 2012-04-16 Sun Pharma Advanced Res Co Ltd Stable pharmaceutical composition
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
IN2014MN01819A (https=) * 2012-03-05 2015-07-03 Univ Ramot
TWI486341B (zh) * 2012-05-18 2015-06-01 高雄醫學大學 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法
US9863949B2 (en) * 2013-05-31 2018-01-09 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents
DK3052101T3 (da) * 2013-10-04 2019-12-16 Prolynx Llc Konjugater af sn-38 med langsom frigivelse
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015118338A1 (en) * 2014-02-07 2015-08-13 Mission Therapeutics Limited Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways
WO2015183876A1 (en) * 2014-05-28 2015-12-03 Memorial Sloan Kettering Cancer Center Bimodal fluorophore-labeled liposomes and associated methods and systems
CA2957721C (en) * 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016028636A1 (en) 2014-08-16 2016-02-25 Memorial Sloan Kettering Cancer Center Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods
JP6378584B2 (ja) 2014-08-29 2018-08-22 キヤノン株式会社 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム
US10196412B2 (en) * 2014-12-24 2019-02-05 The Board Of Trustees Of The Leland Stanford Junior University Probe for imaging PARP-1 activity
PL3560924T3 (pl) 2015-04-02 2021-10-11 Merck Patent Gmbh Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm
CA2980462C (en) * 2015-04-07 2023-08-01 The Curators Of The University Of Missouri Nanoparticle immunoconjugates
WO2016176462A1 (en) * 2015-04-28 2016-11-03 University Of Central Florida Foundation, Inc. Methods and compositions for theranostic nanoparticles
EP3337467B1 (en) * 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US10821195B2 (en) 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
ES2941968T3 (es) 2015-10-01 2023-05-29 The Whitehead Institute For Biomedical Res Marcaje de anticuerpos
US11154538B2 (en) 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
CN109069666B (zh) 2016-04-29 2023-04-04 纪念斯隆凯特琳癌症中心 使靶向颗粒穿透、分布和响应于恶性脑肿瘤中的组合物和方法
CN106084005B (zh) * 2016-06-15 2020-02-14 广州军区广州总医院 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用
CN107050471A (zh) 2016-12-27 2017-08-18 中国药科大学 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP2021510702A5 (https=)
Bonelli et al. Precision medicine in gastric cancer
Chen et al. Improving radiotherapy in cancer treatment: Promises and challenges
Aghajanian et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Sandler et al. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases
Drost et al. Opportunities and hurdles in the treatment of BRCA1-related breast cancer
Mauclet et al. Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab
WO2014172376A3 (en) Markers of tumor cell response to anti-cancer therapy
JP2017519006A5 (https=)
WO2010063011A3 (en) Methods for the treatment of infections and tumors
JP2012529021A5 (https=)
WO2012061683A3 (en) Methods for treating cancer
JP2012528890A5 (https=)
Arrighetti et al. Drug combinations with HDAC inhibitors in antitumor therapy
Rotolo et al. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach
Sandomenico et al. Bevacizumab in non small cell lung cancer: development, current status and issues
Dong et al. Advances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer
Crinò et al. Present and future treatment of advanced non–small cell lung cancer
Miao et al. Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway
AU2017324860A1 (en) PD-1 specific aptamers
Voigtlaender et al. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism
Folprecht Liver metastases in colorectal cancer
Voorhees et al. Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma
US20220288404A1 (en) Methods for applying tumor treating fields in combination with cancer treating therapeutics
JPWO2019140271A5 (https=)